Comparative Pharmacology
Head-to-head clinical analysis: SEROSTIM LQ versus WYOST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEROSTIM LQ versus WYOST.
SEROSTIM LQ vs WYOST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
WYOST is a small molecule inhibitor that selectively targets and inhibits the kinase activity of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), thereby blocking downstream signaling pathways involved in cell proliferation and survival.
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
300 mg intravenously every 4 hours.
None Documented
None Documented
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Terminal elimination half-life: 12-15 hours; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10%
Category C
Category C
Growth Hormone
Growth Hormone